Recent advances in gestational trophoblastic disease

Advances in the last 20 years have led to a better understanding of the process of gestational trophoblastic disease (GTD), and consequently to improved diagnosis, management, and prognosis. Patients with GTD should be registered at a trophoblastic disease center fur follow-up, and those with persistent disease should receive chemotherapy, methotrexate, and folinic acid for low-risk disease, and EMACO (etoposide, actinomycin-D, methotrexate, vincristine, and cyclophosyhamide) for high-risk disease, without loss of fertility. Most patients with relapsing or resistant disease can be treated effectively with surgery and/or cisplatin in EP/EMA (etoposide, platinum-etoposide, methotrexate, actinomycin-D) combination.